ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2832

The Effect Of Maternal Antimalarial Intake During Pregnancy On The Risk Of Neonatal Lupus

Julie Barsalou1, Edgar Jaeggi2 and Earl D. Silverman1, 1Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, 2Cardiology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Antimalarial drugs, neonatal disorders, pediatric rheumatology and pregnancy

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects: Pregnancy

Session Type: Abstract Submissions (ACR)

Background/Purpose: Neonatal Lupus (NLE) results from passive transfer of anti-Ro and/or anti-La antibodies to the fetus during gestation. It has been suggested that prenatal exposure to hydroxychloroquine (HCQ) reduces the risk of cardiac NLE through disruption of toll-like receptors signalling.  The effect of HCQ on the risk of extra-cardiac NLE has not been specifically studied. The aim of this study was to assess if maternal intake of HCQ or chloroquine throughout pregnancy reduces the risk of NLE in the offspring.  We hypothesized that these drugs would confer protection against NLE.

Methods: A case-control study was performed on a large single-center cohort of NLE and unaffected children, on whom prospective data has been collected since 1984.  Inclusion criteria were: (1) first child born from a mother positive for anti-Ro and/or anti-La antibodies with a diagnosis of either cutaneous lupus, systemic lupus erythematosus, Sjogren’s syndrome, dermatomyositis or rheumatoid arthritis and, (2) assessment of the child in the NLE clinic at least once in his first 6 months of life. Descriptive statistics and logistic regressions were performed.

Results: The study population consisted of 220 children, of whom 62 were exposed to HCQ or chloroquine throughout gestation (Table).  NLE was diagnosed in 98 patients; 12 had cardiac NLE (11 congenital heart block and 1 cardiomyopathy).  Neutropenia (n=41) was the most frequent extra-cardiac NLE feature followed by hepatitis (n=36), skin involvement (n=32), thrombocytopenia (n=4) and extraventricular obstructive hydrocephalus (n=4).  One hundred and twelve children did not develop NLE.  Ten children were classified as having no cardiac NLE involvement but could not be diagnosed as true unaffected children as one or more blood test components were missing.  No statistically significant protective effect of HCQ or chloroquine exposure was found on the risk of NLE (OR 0.79; p=0.45).  Similar results were found when extra-cardiac NLE cases were analyzed separately (OR 0.85; p=0.60). Only 1 of 62 children exposed to HCQ or chloroquine developed cardiac-NLE compared to 11 of 158 unexposed children (OR 0.22; p=0.19). On multivariable logistic regression, anti-La titer ≥100 U/mL was the only significant predictor of NLE (OR 2.23; p=0.03).  The mother’s age, diagnosis, intake of azathioprine, anti-Ro titers ≥50 U/mL and the child’s gender did not significantly impact on the risk of NLE.

Conclusion: In the largest single-center case-control study of children born to anti-Ro and/or anti-La antibody positive women diagnosed with a connective tissue disease, HCQ or chloroquine exposure throughout gestation did not result in a significantly lower risk of NLE. High titers of anti-La antibodies in the mother were associated with an increased risk of NLE.

Table. Characteristics of mothers of NLE cases and unaffected children

 

NLE  (n=98)

Unaffected children (n=112)

p value

Mothers

 

 

 

   Age at birth of child

31.7 ± 4.8

32.2 ± 4.6

0.44

   Diagnosis

 

 

0.13

     SLE or cutaneous lupus   

71 (72)

93 (83)

 

     Sjogren’s syndrome    

20 (21)

12 (11)

 

     Others

7 (7)

7 (6)

 

   Anti-Ro ≥50 U/mL*

62 (67)

63 (66)

0.96

   Anti-La ≥100 U/mL§

26 (28)

14 (14)

0.01

   On HCQ or chloroquine

26 (27)

35 (31)

0.45

   On azathioprine

5 (5)

13 (12)

0.09

   On prednisone

28 (29)

40 (36)

0.32

   Older child with CHB

1 (1)

2 (2)

1.00

Mean±SD; n (%)

*n=93 NLE and 95 unaffected children; §n=94 NLE and 103 unaffected children


Disclosure:

J. Barsalou,

GlaxoSmithKline,

9;

E. Jaeggi,
None;

E. D. Silverman,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-effect-of-maternal-antimalarial-intake-during-pregnancy-on-the-risk-of-neonatal-lupus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology